While the current review highlights the large body of evidence examining BC survivorship, several gaps in the evidence base are noted, including BC survivors with BRCA1/2 gene mutations, women receiving tailored treatments (including emerging treatments such as immunotherapy/targeted therapies), those of low socioeconomic status, and the unique experiences of BC survivors with multimorbidity and complex health care needs. The gene discussed is BRCA1; the disease is breast cancer.